Background: BPDE-DNA were cross-sectionally associated with active smoking in a large general population sample (Petruzzelli, 1998). Aim: to assess interaction between smoking and BPDE-DNA as predictor of respiratory outcomes over a 18-year follow-up. Methods: n=750 subjects from two population-based studies in Pisa, Italy, were investigated at baseline (PI1 1991-93) and follow-up (PI2 2009-11) through a questionnaire on health status and risk factors, spirometry and blood analyses. Subjects were classified as: class 1, positive BPDE-DNA heavy smokers (≥ 12 cig./day - population median value); class 2, positive BPDE-DNA light smokers (< 12 cig./day); class 3, negative BPDE-DNA smokers; class 4, ex/never smokers (reference category). Multiple logistic regression models, adjusted for sex and age, estimated the risk of respiratory outcomes at follow-up among the considered classes. Results: there were 4.3%, 2.5%, and 22.8% of subjects in class 1, 2, and 3, respectively. BPDE-DNA positivity per se was not significantly related to any outcomes. Class 1 showed significantly higher risks of developing COPD (OR 4.53 CI 1.84-11.16), asthma attacks (OR 3.48 CI 1.28-9.47), and dyspnoea (OR 2.47 CI 1.06-5.75), while class 2 was not related to any outcome. Higher risks for developing respiratory symptoms/diseases were found also in class 3 but with lower ORs than in class 1. Conclusions: BPDE-DNA along with smoking may predict poor respiratory outcomes, particularly respiratory diseases/symptoms in heavier smokers.
Presence of serum antibodies anti-benzo(a)pyrenediol epoxide (BPDE-DNA) and tobacco smoking as predictors of respiratory outcomes
Pistelli, Francesco;Maio, Sara;Baldacci, Sandra;Carrozzi, Laura;Viegi, Giovanni
2020-01-01
Abstract
Background: BPDE-DNA were cross-sectionally associated with active smoking in a large general population sample (Petruzzelli, 1998). Aim: to assess interaction between smoking and BPDE-DNA as predictor of respiratory outcomes over a 18-year follow-up. Methods: n=750 subjects from two population-based studies in Pisa, Italy, were investigated at baseline (PI1 1991-93) and follow-up (PI2 2009-11) through a questionnaire on health status and risk factors, spirometry and blood analyses. Subjects were classified as: class 1, positive BPDE-DNA heavy smokers (≥ 12 cig./day - population median value); class 2, positive BPDE-DNA light smokers (< 12 cig./day); class 3, negative BPDE-DNA smokers; class 4, ex/never smokers (reference category). Multiple logistic regression models, adjusted for sex and age, estimated the risk of respiratory outcomes at follow-up among the considered classes. Results: there were 4.3%, 2.5%, and 22.8% of subjects in class 1, 2, and 3, respectively. BPDE-DNA positivity per se was not significantly related to any outcomes. Class 1 showed significantly higher risks of developing COPD (OR 4.53 CI 1.84-11.16), asthma attacks (OR 3.48 CI 1.28-9.47), and dyspnoea (OR 2.47 CI 1.06-5.75), while class 2 was not related to any outcome. Higher risks for developing respiratory symptoms/diseases were found also in class 3 but with lower ORs than in class 1. Conclusions: BPDE-DNA along with smoking may predict poor respiratory outcomes, particularly respiratory diseases/symptoms in heavier smokers.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
